Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy.

ABSTRACT:

Background and aims

Every year, in Europe, acute myeloid leukemia (AML) is diagnosed in thousands of adults. For most subtypes of AML, the backbone of treatment was introduced nearly 40 years ago as a combination of cytosine arabinoside with an anthracycline. This therapy is still the worldwide standard of care. Two-thirds of patients achieve complete remission, although most of them ultimately relapse. Since the FLT3 mutation is the most frequent, it serves as a key molecular target for tyrosine kinase inhibitors (TKIs) that inhibit FLT3 kinase. In this study, we report the conjugation of TKIs onto spherical gold nanoparticles.

Materials and methods

The internalization of TKI-nanocarriers was proved by the strongly scattered light from gold nanoparticles and was correlated

SUBMITTER: Petrushev B 

PROVIDER: S-EPMC4760658 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature